SCHEMBL4537508

SCHEMBL4537508

Nc1cc(C=Cc2cccc(C(F)(F)F)c2)ccn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.59
NOS2 P35228 1/20 0.59
NFE2L2 Q16236 1/20 0.54
FBP1 P09467 1/20 0.48
P4HB P07237 2/20 0.47
DYRK1A Q13627 1/20 0.45
DYRK2 Q92630 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
CHRNB2 P17787 1/20 0.45
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45
CHRNA7 P36544 1/20 0.45
CHRNA4 P43681 1/20 0.45
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HRH4 Q9H3N8 1/20 0.44
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537505 1.00 NOS3 (0.59) NOS3NOS2NFE2L2FBP1P4HB
SCHEMBL4534553 0.81 NFE2L2 (0.54) NFE2L2FBP1P4HBDYRK1ADYRK2
SCHEMBL4534554 0.81 NFE2L2 (0.54) NFE2L2FBP1P4HBDYRK1ADYRK2
SCHEMBL5865516 0.78 CYP19A1 (0.53) NOS3NOS2NFE2L2MAPTMEN1
SCHEMBL31380868 0.78 CYP19A1 (0.53) NOS3NOS2NFE2L2MAPTMEN1
SCHEMBL5865513 0.78 CYP19A1 (0.53) NOS3NOS2NFE2L2MAPTMEN1
SCHEMBL13790316 0.77 NFE2L2 (0.82) NFE2L2FBP1P4HBCHRNB2CHRNB4
SCHEMBL5865029 0.77 GRM4 (0.61) NFE2L2FBP1P4HBDYRK1ADYRK2
SCHEMBL5865031 0.77 GRM4 (0.61) NFE2L2FBP1P4HBDYRK1ADYRK2
Hydrochloric Acid SCHEMBL5865415 0.76 GRM4 (0.59) NFE2L2FBP1P4HBDYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722709-B2 Mineralocorticoid receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-13 US disclosed
US-8722709-B2 Mineralocorticoid receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-13 US disclosed
EP-2638012-A1 PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2013-09-18 EP disclosed
US-20120289551-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2012-11-15 US disclosed
WO-2012064631-A1 PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289551-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS NR3C2, MC2R, AVPR2 NOS3 4352/4885NOS2 4666/4885NFE2L2 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.